Waiting list treatment of hepatocellular carcinoma: When do we need level 1 evidence?

American Journal of Transplantation

Volumn 6, Issue 11, 2006, Pages 2531-2532

  Schwartz, M ^a   Lopez, P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CHEMOEMBOLIZATION; EDITORIAL; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT INDICATION;

CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; WAITING LISTS;

EID: 33750005995     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01572.x     Document Type: Editorial

References (4)

1. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002 May 18; 359: 1734-1739.
2. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442.
3. Llovet JM, Mas X, Aponte JJ et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50:123-128.
4. Yao FY, Bass NM, Nikolai B et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transpl 2003 Jul; 9: 684-692.